Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06537180
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-07-31
Brief Title:
Gender-based Differences in the Outcome of the Treatment of Persistent Septic Shock With Hydrocortisone
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Gender-based Differences in the Outcome of the Treatment of Persistent Septic Shock With Hydrocortisone
Status:
COMPLETED
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to explore the gender-based differences in the outcomes of treatment with hydrocortisone in critically ill patients with persistent septic shock
Detailed Description:
Because of their pleiotropic effects corticosteroids are widely used as adjunctive therapy in sepsis for their anti-inflammatory metabolic and immune-suppressing actions Moreover the treatment benefits of corticosteroids in terms of hemodynamics and organ functions for septic shock were established Hydrocortisone reduces the duration of mechanical ventilation and critical care treatment and reduces the time needed for shock reversal Hydrocortisone use at a daily dose of 400 mg for at least 3 days was associated with survival benefits
Interestingly corticosteroid treatment was reported to be more cost-effective in females than in males with septic shock compared with placebo This may be explained by the fact that sex hormones modulate the expression and sensitivity of glucocorticoid receptors differently potentially influencing the bodys response to cortisol To the best of our knowledge the data available on whether females and males may be more or less likely to acquire a better or worse prognosis of persistent septic shock when treated with hydrocortisone is sparse
The aim of this study is to explore the gender-based differences in the outcomes of treatment with hydrocortisone in critically ill patients with persistent septic shock
Interestingly corticosteroid treatment was reported to be more cost-effective in females than in males with septic shock compared with placebo This may be explained by the fact that sex hormones modulate the expression and sensitivity of glucocorticoid receptors differently potentially influencing the bodys response to cortisol To the best of our knowledge the data available on whether females and males may be more or less likely to acquire a better or worse prognosis of persistent septic shock when treated with hydrocortisone is sparse
The aim of this study is to explore the gender-based differences in the outcomes of treatment with hydrocortisone in critically ill patients with persistent septic shock
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None